Denosumab May Increase the Risk of Local Recurrence in Patients with Giant-Cell Tumor of Bone Treated with Curettage

• DOI: 10.2106/jbjs.17.00057
• Publication Date: 2018-03-21T15:06:13Z
• Authors: Costantino Errani; Shinji Tsukamoto; Giulio Leone; Alberto Righi; Manabu Akahane; Yasuhito Tanaka; Davide Maria Donati
• Keywords: Denosumab; Curettage; Interquartile range; Univariate analysis; Teriparatide; Adjuvant Therapy

Background: Recent clinical studies have suggested that denosumab is associated with tumor response and reduced surgical morbidity in patients giant-cell of bone (GCTB). We therefore evaluated the recurrence-free survival rate who had GCTB an extremity were treated surgery denosumab, to determine influence factors on risk local recurrence. Methods: retrospectively reviewed medical records 408 for a single institution from 1990 through 2013. Two hundred forty-seven underwent curettage (intralesional surgery) high-speed burr, 161 resection. Phenol adjuvant was used 221 247 curettage. also 30 surgically (25 5 resection) 2010 2013 compared their results 378 historical control subjects. The overall minimum duration follow-up 24 months. Results: recurrence rates 60% (15) 25 16% (36) 222 alone. joint preservation 80% (20) 94% (209) Univariate multivariable analyses showed only independent factor poor prognosis when considered. median 85.6 months (interquartile range, 54.3 125.1 months). Viable present all specimens denosumab. Conclusions: There higher cohort exposed Because there substantial differences cohorts randomization not applied, however, causation could be evaluated. Level Evidence: Therapeutic III . See Instructions Authors complete description levels evidence.